The stock of Sana Biotechnology Inc (SANA) has seen a 3.67% increase in the past week, with a -29.92% drop in the past month, and a -20.75% decrease in the past quarter. The volatility ratio for the week is 8.57%, and the volatility levels for the past 30 days are at 7.54% for SANA. The simple moving average for the last 20 days is -7.87% for SANA stock, with a simple moving average of -36.93% for the last 200 days.
Is It Worth Investing in Sana Biotechnology Inc (NASDAQ: SANA) Right Now?
SANA has 36-month beta value of 1.42. Analysts have mixed views on the stock, with 3 analysts rating it as a “buy,” 2 as “overweight,” 2 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for SANA is 121.78M, and currently, short sellers hold a 25.59% ratio of that float. The average trading volume of SANA on October 02, 2024 was 1.57M shares.
SANA) stock’s latest price update
Sana Biotechnology Inc (NASDAQ: SANA)’s stock price has plunge by 1.92relation to previous closing price of 4.16. Nevertheless, the company has seen a 3.67% surge in its stock price over the last five trading sessions. globenewswire.com reported 2024-09-30 that SEATTLE, Sept. 30, 2024 (GLOBE NEWSWIRE) — Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its panel at the Goldman Sachs Cell Therapy Day Conference at 1:00 p.m. ET on Tuesday, October 1, 2024. The presentation will feature a business overview and update by Steve Harr, Sana’s President and Chief Executive Officer.
Analysts’ Opinion of SANA
Many brokerage firms have already submitted their reports for SANA stocks, with Rodman & Renshaw repeating the rating for SANA by listing it as a “Buy.” The predicted price for SANA in the upcoming period, according to Rodman & Renshaw is $16 based on the research report published on June 26, 2024 of the current year 2024.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see SANA reach a price target of $12. The rating they have provided for SANA stocks is “Buy” according to the report published on January 16th, 2024.
JMP Securities gave a rating of “Mkt Outperform” to SANA, setting the target price at $9 in the report published on September 25th of the previous year.
SANA Trading at -17.40% from the 50-Day Moving Average
After a stumble in the market that brought SANA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -64.67% of loss for the given period.
Volatility was left at 7.54%, however, over the last 30 days, the volatility rate increased by 8.57%, as shares sank -24.29% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -30.61% lower at present.
During the last 5 trading sessions, SANA rose by +3.67%, which changed the moving average for the period of 200-days by +17.13% in comparison to the 20-day moving average, which settled at $4.53. In addition, Sana Biotechnology Inc saw 3.92% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SANA starting from Mulligan Richard, who sale 150,000 shares at the price of $4.08 back on Sep 24 ’24. After this action, Mulligan Richard now owns 2,848,121 shares of Sana Biotechnology Inc, valued at $612,570 using the latest closing price.
Mulligan Richard, the Director of Sana Biotechnology Inc, sale 150,000 shares at $3.89 during a trade that took place back on Sep 25 ’24, which means that Mulligan Richard is holding 2,698,121 shares at $583,170 based on the most recent closing price.
Stock Fundamentals for SANA
The total capital return value is set at -0.42. Equity return is now at value -70.51, with -36.94 for asset returns.
Based on Sana Biotechnology Inc (SANA), the company’s capital structure generated 0.22 points at debt to capital in total, while cash flow to debt ratio is standing at -2.43.
Currently, EBITDA for the company is -294.94 million with net debt to EBITDA at 0.19. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.20.
Conclusion
To put it simply, Sana Biotechnology Inc (SANA) has had a mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
